TargetNicotinamide phosphoribosyltransferase(Homo sapiens (Human))
Forma Therapeutics
Curated by ChEMBL
Forma Therapeutics
Curated by ChEMBL
Affinity DataIC50: 0.600nMAssay Description:Inhibition of Nampt (unknown origin) using nicotinamide as substrate preincubated for 15 mins measured after 30 mins by mass spectrometry analysisMore data for this Ligand-Target Pair
TargetNicotinamide phosphoribosyltransferase(Homo sapiens (Human))
Forma Therapeutics
Curated by ChEMBL
Forma Therapeutics
Curated by ChEMBL
Affinity DataIC50: 1.70nMAssay Description:Inhibition of Nampt (unknown origin) using nicotinamide as substrate preincubated for 15 mins measured after 30 mins by mass spectrometry analysisMore data for this Ligand-Target Pair
TargetNicotinamide phosphoribosyltransferase(Homo sapiens (Human))
Forma Therapeutics
Curated by ChEMBL
Forma Therapeutics
Curated by ChEMBL
Affinity DataIC50: 1.90nMAssay Description:Inhibition of Nampt (unknown origin) using nicotinamide as substrate preincubated for 15 mins measured after 30 mins by mass spectrometry analysisMore data for this Ligand-Target Pair
TargetNicotinamide phosphoribosyltransferase(Homo sapiens (Human))
Forma Therapeutics
Curated by ChEMBL
Forma Therapeutics
Curated by ChEMBL
Affinity DataIC50: 2nMAssay Description:Inhibition of Nampt (unknown origin) using nicotinamide as substrate preincubated for 15 mins measured after 30 mins by mass spectrometry analysisMore data for this Ligand-Target Pair
TargetNicotinamide phosphoribosyltransferase(Homo sapiens (Human))
Forma Therapeutics
Curated by ChEMBL
Forma Therapeutics
Curated by ChEMBL
Affinity DataIC50: 2.20nMAssay Description:Inhibition of Nampt (unknown origin) using nicotinamide as substrate preincubated for 15 mins measured after 30 mins by mass spectrometry analysisMore data for this Ligand-Target Pair
TargetNicotinamide phosphoribosyltransferase(Homo sapiens (Human))
Forma Therapeutics
Curated by ChEMBL
Forma Therapeutics
Curated by ChEMBL
Affinity DataIC50: 2.40nMAssay Description:Inhibition of Nampt (unknown origin) using nicotinamide as substrate preincubated for 15 mins measured after 30 mins by mass spectrometry analysisMore data for this Ligand-Target Pair
TargetNicotinamide phosphoribosyltransferase(Homo sapiens (Human))
Forma Therapeutics
Curated by ChEMBL
Forma Therapeutics
Curated by ChEMBL
Affinity DataIC50: 2.40nMAssay Description:Inhibition of Nampt (unknown origin) using nicotinamide as substrate preincubated for 15 mins measured after 30 mins by mass spectrometry analysisMore data for this Ligand-Target Pair
TargetNicotinamide phosphoribosyltransferase(Homo sapiens (Human))
Forma Therapeutics
Curated by ChEMBL
Forma Therapeutics
Curated by ChEMBL
Affinity DataIC50: 2.5nMAssay Description:Inhibition of Nampt (unknown origin) using nicotinamide as substrate preincubated for 15 mins measured after 30 mins by mass spectrometry analysisMore data for this Ligand-Target Pair
TargetNicotinamide phosphoribosyltransferase(Homo sapiens (Human))
Forma Therapeutics
Curated by ChEMBL
Forma Therapeutics
Curated by ChEMBL
Affinity DataIC50: 3.60nMAssay Description:Inhibition of Nampt (unknown origin) using nicotinamide as substrate preincubated for 15 mins measured after 30 mins by mass spectrometry analysisMore data for this Ligand-Target Pair
TargetNicotinamide phosphoribosyltransferase(Homo sapiens (Human))
Forma Therapeutics
Curated by ChEMBL
Forma Therapeutics
Curated by ChEMBL
Affinity DataIC50: 4.40nMAssay Description:Inhibition of Nampt (unknown origin) using nicotinamide as substrate preincubated for 15 mins measured after 30 mins by mass spectrometry analysisMore data for this Ligand-Target Pair
TargetNicotinamide phosphoribosyltransferase(Homo sapiens (Human))
Forma Therapeutics
Curated by ChEMBL
Forma Therapeutics
Curated by ChEMBL
Affinity DataIC50: 4.40nMAssay Description:Inhibition of Nampt (unknown origin) using nicotinamide as substrate preincubated for 15 mins measured after 30 mins by mass spectrometry analysisMore data for this Ligand-Target Pair
TargetNicotinamide phosphoribosyltransferase(Homo sapiens (Human))
Forma Therapeutics
Curated by ChEMBL
Forma Therapeutics
Curated by ChEMBL
Affinity DataIC50: 5.40nMAssay Description:Inhibition of Nampt (unknown origin) using nicotinamide as substrate preincubated for 15 mins measured after 30 mins by mass spectrometry analysisMore data for this Ligand-Target Pair
TargetNicotinamide phosphoribosyltransferase(Homo sapiens (Human))
Forma Therapeutics
Curated by ChEMBL
Forma Therapeutics
Curated by ChEMBL
Affinity DataIC50: 7.5nMAssay Description:Inhibition of Nampt (unknown origin) using nicotinamide as substrate preincubated for 15 mins measured after 30 mins by mass spectrometry analysisMore data for this Ligand-Target Pair
TargetNicotinamide phosphoribosyltransferase(Homo sapiens (Human))
Forma Therapeutics
Curated by ChEMBL
Forma Therapeutics
Curated by ChEMBL
Affinity DataIC50: 29nMAssay Description:Inhibition of Nampt (unknown origin) using nicotinamide as substrate preincubated for 15 mins measured after 30 mins by mass spectrometry analysisMore data for this Ligand-Target Pair